Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases by de Souza, Camila Ferreira et al.
Hindawi Publishing Corporation
Dermatology Research and Practice
Volume 2012, Article ID 156068, 14 pages
doi:10.1155/2012/156068
Review Article
Biomarkers as KeyContributors in Treating Malignant
MelanomaMetastases
Camila Ferreirade Souza, Alice SantanaMorais, andMiriamGalvonasJasiulionis
Pharmacology Department, Federal University of S˜ ao Paulo, 04039-032 S˜ ao Paulo, SP, Brazil
Correspondence should be addressed to Miriam Galvonas Jasiulionis, mjasiulionis@gmail.com
Received 12 May 2011; Accepted 17 August 2011
Academic Editor: G´ erald E. Pi´ erard
Copyright © 2012 Camila Ferreira de Souza et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Melanoma is a human neurocristopathy associated with developmental defects in the neural crest-derived epidermal melanocytes.
At the present time, at least three hypotheses were identiﬁed that may explain melanoma aetiology, as follows: (1) a model of linear
progression from diﬀerentiated melanocytes to metastatic cancer cells (2) a model involving the appearance of melanoma stem-
like cells, and (3) an epigenetic progenitor model of cancer. Treating metastatic melanoma is one of the most serious challenges
in the 21st century. This is justiﬁed because of a subpopulation of cells presenting a remarkable molecular heterogeneity, which is
able to explain the drug resistance and the growing mortality rates worldwide. Fortunately, there are now evidences sustaining the
importance of genetic, epigenetic, and metabolomic alterations as biomarkers for classiﬁcation, staging, and better management
of melanoma patients. To illustrate some fascinating insights in this ﬁeld, the genes BRAFV600E and CTLA4 have been recognized
as bona ﬁde targets to beneﬁt melanoma patients. Our research attempts to carefully evaluate data from the literature in order to
highlight the link between a molecular disease model and the key contribution of biomarkers in treating malignant melanoma
metastases.
1.Introduction
Historically, the ﬁrst report of malignant tumor forma-
tions in the skin from anatomic sites where nevi had
previously existed was proposed by Virchow [1]. Melan-
otic nevi and cutaneous melanoma are deﬁned as human
neurocristopathies associated with developmental defects
in the neural crest-derived epidermal melanocytes. One
consequence of changes in skin melanocyte development
is its malignant transformation to cutaneous melanoma
[2, 3]. In the sixties, Clark and coauthors described three
diﬀerent clinical types of primary human skin melanomas
based on histological growth patterns: superﬁcial spreading
melanoma (SSM), nodular melanoma (NM), and lentigo
maligna melanoma (LMM). Any melanoma, except NM,
was showed to present a biphasic growth pattern: an initial
and long period of time characterized by superﬁcial growth
followed by rapid deeper invasion. Curiously, NM subtype
does not appear to have a superﬁcial growth component,
and it was characterized by uniform invasiveness. Moreover,
they observed ﬁve anatomic levels of invasion (Clark’s levels
I–V), based on extracellular matrix architecture, as follows:
level I (tumor cells were above the basement membrane—in
situ melanoma), level II (tumor cells invading the papillary
dermis),levelIII(tumorcellsinvadingbothpapillaryandthe
upper part of reticular dermis) level IV (tumor cells showing
any signiﬁcant invasion of the reticular dermis, where
collagen begins to be organized into bundles), and level
V (tumor cells invading subcutaneous tissues—metastatic
melanoma). Afterwards, Reed (1976) identiﬁed acral lentigi-
nousmelanoma(ALM)asanotherhistopathologicalsubtype
of this disease, which occurs in glabrous (palmar, plantar,
and subungual) skin [4, 5]. As a whole, higher levels
of invasion were correlated with poor prognosis [4]. The
main purpose of this article is to discuss relevant points
of view on current advances and limitations in studying
and treating malignant melanoma, emphasizing how early
events driving tumorigenesis might help us to understand
metastatic disease, and the key role of discovering new
biomarkers in this scenario.2 Dermatology Research and Practice
2. MalignantMelanoma Progression:From
NormalMelanocytestoMetastaticStage
Nowadays, there are three main hypotheses proposed to
explain malignant melanoma origin and progression. Firstly,
there is a linear invasion model proposed by Clark et al.
[6], in which melanoma begins to develop gradually from
diﬀerentiated precursor melanocytes. The earliest step of
this neoplastic process is viewed as a focal proliferation
of mature melanocytes, and the resultant lesion is known
as common acquired melanocytic nevus. Afterwards, there
is a stage in which a melanocytic nevus is comprised
by melanocytes showing nuclear atypia and an aberrant
diﬀerentiation program, and the resultant premalignant
lesion is known as melanocytic dysplasia. Some dysplastic
or atypic melanocytes have spreading capability within
the epidermis and a distinctive proﬁle of invasive growth
conﬁned to the papillary dermis. This primary malignant
lesion is termed radial growth melanoma (RGP) and does
not form metastasis. The appearance of a new population
of cells with aggressive biological potential, growing in an
expansive way and perpendicular direction, and invading
the reticular dermis is correlated to a more dangerous step
known as primary vertical growth melanoma (VGP). VGP
melanoma is clinically dangerous because of a cell subpopu-
lation presenting competence for metastasis. However, these
cells and surrounding environment do not have suﬃcient
angiogenesis or lymphangiogenesis capabilities to support
metastases. VGP melanoma cells can progress to a metastatic
stage, in which deeper invasion of the subcutaneous tissues
and extensive neoangiogenesis are important properties. As
a hallmark of metastatic developmental stage, a cluster of
progeny cells are able to colonize distant tissues from the
origin of the primary melanoma [6, 7]. The molecular
mechanisms of invasion and metastasis require changes in
cell motility gene expression, and these processes occur by
coordination of cell extension, adhesion, deadhesion, and
contraction steps [7]. Importantly, not all melanomas arise
frommelanocytesthatpassthroughtheatypicalmelanocytic
nevus stage and not all atypical melanocytes progress to
the malignant disease. The evidence in which malignant
melanoma does not universally arise from nevus and that
this may be the exception rather than the rule was proposed
by Clark et al. in 1969 [4]. Hence, two other models were
proposed. One of them is a melanoma stem cell and tumor
microenvironment model, in which melanoma stem-like
cells (tumor-initiating cells) lead directly to the observed
clinical outcomes without progressing through intermediate
stages.Additionally,ﬁbroblasts,endothelialcells,andinﬂam-
matory cells from the tumor microenvironment would be
able to contribute to and support metastases [8]. Finally,
there is an epigenetic progenitor model to explain the
common basis of cancer proposed by Feinberg et al. [9], in
which early epigenetic changes occur in tissue-speciﬁc (non-
cancerous) stem-cells. According to this polyclonal model,
this primary alteration can be due to events within the stem
cells themselves, the inﬂuence of the stromal compartment,
or microenvironmental injury. Later, epigenetic plasticity
and genetic alterations would drive tumor progression [9].
Thus, the epigenetic progenitor model of cancer provides
new insights to understand the malignant transformation.
Since global epigenetic abnormalities accumulate during
cancer development, it is reasonable to hypothesize that
deregulation in epigenetic mechanisms may be involved in
melanoma aetiology.
3.Staging of Metastatic Melanoma at Diagnosis
andPrognosis
Malignant melanoma is a complex disease and patients
diagnosed at metastatic stage have a poor prognosis because
of the remarkable molecular heterogeneity and resistance
of melanoma cells to apoptotic processes and classical
chemotherapy interventions [10, 11]. Metastatic melanoma
cells tend to disseminate to multiple organs, including but
not limited to brain, lungs, liver, and bone. Currently,
there is no eﬀective cure for advanced disease. Complete
remissions after chemotherapeutic regimens rarely beneﬁt
more than 20% of patients [11]. According to the National
Cancer Institute 68,130 new cases and 8,700 deaths from
malignant melanoma were estimated in the United States in
2010 (available at http://www.cancer.gov/). Taken together,
these data suggest that malignant melanoma represents an
important public health problem in the 21st century.
As a result of multivariate analysis of 7,972 patients
with metastatic melanoma performed by American Joint
Committee on Cancer (AJCC), the clinicopathologic factors
that deﬁne the M-category strata to the conventional TNM
(tumor, node, metastasis) system should be evaluated by
two dominant criteria. The ﬁrst one is the site(s) of distant
metastases, as follows: M1a—nonvisceral (skin, subcuta-
neous (soft) tissue, or distant lymph nodes), M1b—lung or a
combination of lung and skin or subcutaneous metastases,
and M1c—the other visceral metastatic sites. The second
criterion is the increased lactic dehydrogenase (LDH) serum
level that is a powerful and an independent predictor of
survival among patients with stage IV melanoma. In this
case, patients are all categorized as M1c, regardless of the
site(s) of their distant disease. These staging for metastatic
melanoma have been approved by the International Union
Against Cancer (UICC) TNM Committee. One-year survival
ratesamong7,972stageIVpatientswere62%forM1a(better
prognosis), 53% for M1b (intermediate prognosis), and 33%
for M1c (worst prognosis) melanomas (P<0.0001). The
overall prognosis of all patients with stage IV melanoma
remains poor, even among those who are classiﬁed as
M1a. For this reason, the Melanoma Staging Committee
recommended no stage grouping for stage IV melanomas to
clinical trial studies [12].
4. The KeyRole of BiomarkersinMelanoma
Classiﬁcation Reﬁnement
It is well known that malignant melanoma development
correlates with genetic alterations and sun exposure since
ultraviolet radiation is the major risk factor [13]. Currently,
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canonical and variant histone marks, nucleosome position-
ing, and noncoding RNAs (speciﬁcally microRNAs), are
emerging as dynamic hallmarks of earliest and later events
driving melanoma genesis and progression [14–16]. To
illustrate this, we recently demonstrated that nonmetastatic
and metastatic murine melanoma cells treated in vitro,
respectively, with Trichostatin A and 5-aza-2 -deoxycytidine
(pharmacological inhibitors of histone deacetylases enzymes
and DNA methyltransferases, resp.) showed reduction of
tumor growth in vivo when inoculated in syngeneic mice.
Moreover, we observed changes in epigenetic machinery
components even in premalignant melanocytes, suggesting
that epigenetic marks act as key contributors to melanocyte
full malignant transformation and melanoma aggressiveness
[16]. A recent study has pointed out the role of chemicals as
melanoma risk factors,such as the polychlorinated biphenyls
pesticides [17]. This study uncovers the existence of other
risk factors associated with melanoma development, which
are not yet well characterized.
The classiﬁcation scheme recommended by The World
HealthOrganization(WHO)toidentifyprimarymelanomas
distinguishes four main melanoma subtypes based on
histological growth patterns: SSM, LMM, NM, and ALM
[4, 5, 18]. However, there are reasons to be concerned
about classical classiﬁcation schemes. There is a group
of pathologists who recognize a subgroup designated as
malignant melanoma of unclassiﬁable histogenetic type
[18]. The meta-analysis study conducted worldwide showed
that histological type of primary melanomas did not have
predictive clinical outcome once systemic metastasis had
developed [19]. Moreover, distinct types of melanomas had
diﬀerent susceptibility to ultraviolet light [20], suggesting
that not all melanomas arise from areas exposed to the sun.
Becauseofthis,anotherclassiﬁcationsystemhasbeenusedto
classify primary melanomas arising from nonglabrous skin,
as follows: melanomas occurring in nonchronically or inter-
mittentlysun-damagedskinandinchronicallysun-damaged
skin. This classiﬁcation system comprises acral melanomas
and mucosal melanomas, which can be separated based on
patterns of chromosomal aberrations [20]. Furthermore, it is
well known that melanoma cells express multiple molecular
phenotypes. This feature has been associated with the pres-
enceofasubpopulationofcellsshowingstem-cellproperties,
such as the ability to diﬀerentiate into several mesenchymal
lineages, including melanocytic cells [8]. Importantly, a
recent study reported the presence of a temporarily distinct
subpopulation of slow-cycling melanoma cells, which seem
to be an essential feature for continuous tumor growth
[21]. Apart from genetic alterations, another possible expla-
nation to melanoma cells heterogeneity is the epigenetic
reprogramming as an adaptation of cells to a sustained
microenvironmental stress condition [9, 16]. Taken together,
these ﬁndings highlight the urgency in understanding some-
how molecular variables can predict subtypes biologically
more homogeneous to reﬁne the WHO melanoma clas-
siﬁcation scheme and improve melanoma treatment. In
this way, current studies have been performed to identify
reliable biomarkers to predict melanoma clinical outcome.
Unfortunately, most of the studies characterizing “omics”
expression do not emphasize or describe with suﬃcient
detailsanymelanomaclassiﬁcationsystem.Thisscenariowas
able to explain, at least in part, the poor correlation between
discovered biomarkers from basic research with results of
clinical trials and their potential clinical exploitation. Here,
we present a compilation of studies conducted according to
the new hypothesis, in which identifying patient’s subgroups
more biologically homogeneous needs an integrated analysis
involvinghistomorphologicalmeasurements,transcriptome,
proteomic and metabolomic studies, and epidemiologic and
clinical variables. Such data suggest that this evaluation
scheme is more accurate than the currently classiﬁcation
based only on histological features.
Study 1. Alonso et al. [22] performed an integrated study
based on the combination of tissue microarray approach
with clinical and histopathological data. The aim of the
study was to identify new proteins diﬀerentially involved
at speciﬁc stages of melanoma as candidate biomarkers
for target therapy. A total of 175 human specimens were
retrospectively evaluated, including 10 nevi, 28 RGP primary
melanomas, 66 VGP primary melanomas, and 71 metastases
(34skinmetastasesand37nodalmetastases).Asaresult,this
study demonstrated that each step in malignant melanoma
development was characterized by the expression of a
speciﬁc signature. Among the most detected alterations
observedwereupregulationofcyclinA,cyclinD1,CDK1and
CDK2 (cell cycle regulatory proteins), survivin (apoptosis),
and active form of STAT1 (transcription factor) in RGP
melanomas relative to nevi; simultaneous upregulation of
Ki-67 and downregulation of p27KIP1 (cell cycle regulatory
proteins) in VGP melanomas relative to RGP melanomas
or benign lesions; upregulation of cyclin D1 and cyclin
D 3 ,a n dal o s so fp 1 6 INK4a (cell cycle regulatory proteins),
and downregulation of BCL2 (apoptosis) and MUM1 (tran-
scription factor) in metastatic melanomas relative to VGP
melanomas. Although many of identiﬁed changes are stage
speciﬁc, it seems that an increasing degree of expression
of cyclins and CDK(s), in conjunction with a loss of CDK
inhibitors, facilitate the progression to advanced clinical and
histological stages. Curiously, cyclin D1 protein expression
w a sn e g a t i v ei na l ln e v ia n dm a r k e d l ye x p r e s s e di nR G P
melanomas and metastases, and signiﬁcantly downregu-
lated in VGP melanomas. As discussed by authors, these
ﬁndings suggest a critical role for cyclin D1 in melanoma
pathology, and illustrate how melanoma progression is
meticulously and dynamic coordinated. Thus, to progress
from nevus to metastasis, each step is distinguished by the
expression of a characteristic set of molecular marks or,
perhaps, by their diﬀerential levels of expression as those
observed for cyclin D1. In fact, our experience with global
gene expression analysis using high-density oligonucleotide
microarrays in a murine melanoma progression model
supports this idea, in which several kinetic proﬁles of gene
expression from nontumorigenic melanocytes to metastatic
melanoma cell lineage were observed (see [16], and data not
published). Moreover, Alonso’s group [22]o b s e r v e dad e f e c -
tive deregulation of apoptosis by upregulation of survivin
protein expression from nevi to RGP, VGP, and metastatic4 Dermatology Research and Practice
melanoma,suggestingaparallelbetweenapoptosisresistance
and melanoma progression. Since 30 patients had VGP
and metastatic melanomas, a simultaneous analysis in the
expression of a combination of relevant molecular markers
in the same patients from both stages was performed.
In this way, this study also developed a predictor model
for survival identifying a group of patients with shorter
overall survival associated with VGP melanoma, which was
related to the absence of p16INK4a or the presence of BCL6
protein expression in conjunction with either high Ki-67
expression or positive p21CIP1 [22]. Although apparently
paradoxical because of its cyclin-dependent inhibitory and
tumor suppressor activities, a recent study reported that
p21CIP1 may also act as a tumor promoting factor by
inhibiting apoptosis [23].
Study 2. Curtin et al. [20] performed an elegant study
in which they compared genome-wide alterations in the
number of DNA copies, and mutational status of BRAF
and NRAS, in attempt to clarify the relationship among
clinical heterogeneity, histological characteristics, degree of
sun exposure and susceptibility to ultraviolet light, and
genomic instability. A total of 126 tumor specimens were
evaluated and classiﬁed in four groups based on their
location and diﬀerences in the degree of sun exposure, as
follows: 36 specimens of acral melanoma, 20 specimens of
mucosal melanoma, 30 specimens of melanoma arising from
skin with chronic sun-induced damage, and 40 specimens
of melanoma arising from skin without chronic sun-induced
damage. All primary melanomas had an invasive component
in which tumor cells predominated over stromal cells.
As a result, they observed and discussed that there were
distinct sets of genetic alterations, suggesting that melanoma
develops by diﬀerent mechanistic pathways in response
to diﬀerent selective inﬂuences. As a whole, there were
marked diﬀerences in aberrant genomic regions among the
groups. These diﬀerences were more pronounced between
melanomas on skin that were relatively or absolutely pro-
tected from the sun (glabrous skin in acral melanomas and
mucosal epithelia membranes in mucosal melanomas) and
melanomas on skin exposed to the sun. Acral and mucosal
melanomas had a signiﬁcantly higher degree of chromoso-
malaberrations,buttheyinvolveddiﬀerentgenomicregions.
The commonest alterations distinguishing these two groups
were gains involving the CCND1 locus, gains and losses
involving chromosomes 22 and 4q, respectively, in the group
exposed chronically to the sun, while the losses involving
chromosome 10q were more frequently observed in the
group with no skin-induced damages. Speciﬁcally, eighty-
one percent of tumors on skin without chronic sun-induced
damage frequently had mutation in BRAF together with
fewer copies of PTEN, or mutations in NRAS alone. In
accordance to this ﬁnding and as reviewed by authors,
BRAF and NRAS genes do not show typical ultraviolet
“ﬁngerprint” mutations. On the other hand, the majority of
melanomas in the other three groups did not have mutations
in BRAF or NRAS but instead had increased copy number
of the downstream genes CCND1 or CDK4. These ﬁndings
implicate CDK4 and CCND1 as independent oncogenes in
melanomas presenting this genetic background (absence of
mutations in BRAF and NRAS). As discussed by authors,
their ﬁndings are of great clinical importance because of
possible prevention and potential therapeutic strategies.
Hence, in melanomas in which BRAF or NRAS mutations
are present, they would be expected to be responsive to
therapeutic interventions targeting the RAS-RAF-ERK and
PI3K pathways, such as sorafenib [20]. In parallel, a recent
multicentric study reported that the treatment of metastatic
melanomas carrying BRAFV600E mutations with a selective
small molecule inhibitor PLX4032 resulted in complete or
partial regression of disease in most of the patients [24].
Studies 3 and 4. Viros et al. [25]p e r f o r m e das t u d y
based on genotype-phenotype point of view, in which they
reﬁned a current classiﬁcation scheme of distinct melanoma
subtypes proposed by WHO, integrating to this existing
classiﬁcation model continuous variables, such as a panel
of histomorphological measures (scatter of intraepidermal
melanocytes, nesting of intraepidermal melanocytes, cyto-
plasmic pigmentation of neoplastic melanocytes, cell size,
cell shape, nuclear size, and nuclear shape), and unordered
categorical variables, such as anatomic site, WHO subtype,
melanomas arising from skin with and without evidence of
chronic sun-induced damage, acral grouping and gender,
and correlated them with the mutation status of BRAF
(exon 15, which includes codon 600) and NRAS (exons 1
and 2, only if no BRAF mutation was detected, since there
is a very low cooccurrence of these aberrations). A total
of 302 primary radial growth melanomas were evaluated,
and areas with vertical growth were excluded, except in
the case of nodular melanoma, in which the assessment
was made in any small intraepidermal component adjacent
to the nodular portion wherever possible. The aim of this
study was improving melanoma classiﬁcation by integrating
genetic and morphologic features, and clinical information
to provide a better understanding regarding malignant
melanoma “histogenetic” origin and group melanoma in
a more homogeneous biological category. As a result, the
authors observed that melanomas with BRAF mutations
showed distinct morphological features, such as increased
upward migration and nest formation of intraepidermal
melanocytes, thickening of the involved epidermis, and
sharper demarcation to the surrounding skin, and had
larger, rounder, and more pigmented tumor cells compared
to melanomas without BRAF mutation. Moreover, among
the clinical variables, they identiﬁed age <55 years as the
single most predictive factor for BRAF mutation. When this
age cutoﬀ was applied to an independent cohort of 4,785
patients, a better prognosis associated to the development of
metastases to regional nodes were observed whereas patients
that, on the basis of their age, were less likely to have a
BRAF mutant melanoma more frequently displayed satellite,
in-transit metastasis, and visceral metastasis. On the other
hand, NRAS mutation failed in distinguishing melanomas
on the basis of these morphological features. Finally, authors
discussing the importance of improving the classiﬁcation
scheme in two ways: to facilitate stratiﬁcation for therapy, as
well as retrospective analysis of existing clinical trials [25].Dermatology Research and Practice 5
Table 1: Eﬀects of candidates of oncogenic biomarkers in melano-
ma progression.
Biomarker Biological eﬀect(s) associated with
biomarker upregulation Reference
ABCB5




BPAG1 Detected as autoantibody in serum of
melanoma patients [32]
BRAF Mediated melanoma cell resistance to
anoikis [33]
BRG1
Promoted epigenetic changes in
extracellular matrix/adhesion gene




nestin Associated with poor prognosis [35]
DEK Associated with gain of chromosome 6p,
proliferation, and chemoresistance [36]
DNMT3B Predicted overall survival in patients with
lymph node metastases [27]
HIF1A Associated with a prosurvival role [37]
Integrin
α4β1
Required for lymphangiogenesis and
metastasis [38]
JARID1B Required for continuous tumor growth [21]




Regulated morphological plasticity and
determined modes of melanoma cells
migration and invasion
[40]
MITF-Mdel Purposed for diagnosis and followup [41]
NG2/MPG Correlated with multidrug resistance [42]
S100A13
Represented a new angiogenic marker
favoring the shift from radial to vertical
tumor growth
[43]
TM9SF4 Associated with cannibalism behavior in
metastatic lesions [44]
TSPAN8 Mediated dermal invasion and
progression to metastasis [45]
Vimentin Predicted hematogenous metastasis [46]
WNT5A Mediated melanoma metastasis [47]
The reproducibility of this study was validated by Broekaert
et al. [26] who conﬁrmed that BRAF mutation deﬁne a
subsetofmelanomasmorebiologicallyhomogeneous,which
metastasized more frequently to regional lymph nodes and
are commonly observed in younger people. Finally, the
authors discussed the heterogeneity exhibited by melanomas
without BRAF mutations, in which a subgroup having
very similar clinical and morphological characteristics as
those observed in melanomas with BRAF mutation was
observed, suggesting the possibility that they are biologically
related and, perhaps, alternative genes acting immediately
downstream of BRAF,s u c ha sMEK1 and MEK2 could be
candidates for target therapy in this context [26].
Study 5. Nguyen et al. [27] hypothesized that melanoma
AJCC stages could be classiﬁed by epigenetic biomarkers.
The authors performed a study in which specimens from 15
primary cutaneous melanomas, 16 lymph node metastases,
and 31 distant metastases were assessed to determine the
signiﬁcance of microRNA-29 isoform C and DNMT3A and
DNMT3B expression in melanoma progression and clinical
outcome[27].Moreover,theywereinterestedindetermining
their potential utility as hallmarks of CpG island methylator
phenotype (CIMP), which is associated with melanoma
aggressiveness through inactivation of tumor suppressor
genes and tumor-related genes, and methylation of MINT
(noncoding methylated-in-tumor) loci [27, 28]. As a result,
they observed that the downregulation of microRNA-29c
was associated with hypermethylation status of tumor-
r e l a t e dg e n e sa n dM I N Tl o c i ,a n di n v e r s e l yc o r r e l a t e d
with DNMT3A and DNMT3B expression in metastatic
tumors. These ﬁndings suggest the antagonistic role of
microRNA-29c in regulating DNMT3 expression, and that
its potential tumor suppressor activity is lack and correlate
with melanoma progression. Furthermore, expression of
microRNA-29c correlated with DNMT3B expression was
found signiﬁcant as prognostic factor predicting overall
survival in patients with lymph node metastases. Hence,
the authors discussed that microRNA-29c expression may
potentially provide signiﬁcant information by diﬀerentiating
metastaticmelanomainthewaytoimproveadjuvanttherapy
for advanced disease [27].
Study 6. Recently, Abaﬀy et al. [29] exploited an emerging
approach based on volatile metabolomic ﬁngerprint, that
does not alter tissue morphology and potentially permits to
discover new melanoma biomarkers (metabolites of interest
that change in response to melanoma development) to
improve early diagnosis and positive clinical outcome for
patients. As a result, the authors observed that a diﬀerential
metabolic signature of melanoma does exist, and was
characterized predominantly by three volatiles expressed in
fresh and frozen melanomas: 4-methyl decane, dodecane,
and undecane. Curiously, the ﬁrst one is a methylated alkane
previously listed as a biomarker of lung cancer, suggesting
an increased methylation process in melanoma. Moreover,
the presence of secondary metabolites of membrane lipid
peroxidation, such as dodecane and undecane, indicates an
oxidative stress environment [29]. These ﬁndings are in
accordance to works performed by our group, in which
sustained stress resulted in higher levels of reactive oxygen
species in the microenvironment [30]. This feature was asso-
ciated with epigenetic reprogramming of non-tumorigenic
murine melanocytes, involving both DNA methylation and
histone marks, evaluated at transcriptional and posttransla-
tional molecular levels, respectively [16]. Abaﬀy et al. (2010)
also identiﬁed pyridine as a unique volatile biomarker of
nevus. Finally, they emphasized that volatile metabolomic
might help in improving melanoma classiﬁcation schemes
and targeted therapy [29].
The deregulation of oncogenic and tumor suppressor
signaling pathways are key molecular mechanisms promot-
ing melanoma progression. The most recently candidate
biomarkers discovered from human melanoma cell lines and
tumor specimens are shown in Tables 1 and 2.6 Dermatology Research and Practice
Table 2: Eﬀects of candidate of tumor suppressor biomarkers in
melanoma progression.
Biomarker Biological eﬀect(s) associated with
biomarker downregulation Reference
BAK
Weak BAK expression in serum of
patients with melanoma was associated








Associated with advancing clinical stage
of melanoma [28]








Predicted overall survival in patients with
lymph node metastases [27]
Taken together, these data suggest that discovering new
b i o m a r k e r sm i g h tr e p r e s e n tap o w e r f u lt o o li nm e l a n o m a
classiﬁcation reﬁnement and their potential exploitation in
clinical trial designs.
5. TreatingMetastaticMalignantMelanoma
Over the years, ﬁnding an ideal treatment for patients
with advanced melanoma has been the major challenge for
researchers in this area [51]. Meanwhile, the dissemination
of this malignancy to new and distant tissues, with rare
exceptions, is almost a sign of incurable tumor. According
to American Joint Committee on Cancer (AJCC), patients
with stage IV melanoma have a median survival time of
only 8-9 months, with 1-year survival rates of 33%–62%
[12]. This is essentially because no treatment approach has
demonstrated a survival beneﬁt, but eﬀorts have been done.
The basis of treatment for metastatic melanoma is systemic
therapy which addresses the subclinical sites of metastases as
well. On the other hand, locoregional treatment modalities
such as surgery or radiation are usually used as palliative
approaches or as adjuvant in systemic therapy to improve
clinical outcomes [52].
5.1. Classical Systemic Interventions. The systemic therapies
include diﬀerent methods as follows.
(i) Cytotoxic chemotherapy: it has been used for over
three decades and continues to be the standard treat-
ment of metastatic melanoma due to dacarbazine
that is the only chemotherapeutic agent approved by
the Food and Drug Administration (FDA) despite
its modest eﬃcacy. The moderate antitumor activity
of these chemotherapeutic agents led to attempts to
combine them but the latest studies have demon-
strated that higher response rates are associated with
increased toxicity without any survival advantage
when compared with a single-agent regimen [53];
(ii) Immunotherapy: term used for nonspeciﬁc as well as
speciﬁc immunomodulation which, in other words,
means use of natural or manufactured substances
to boost or restore the body’s immune system so
it can better recognize and ﬁght disease [54]. Most
commonly used as adjuvant therapy for melanoma
following surgery but, due to the relative success of
some immunotherapeutic approaches, this strategy
has fuelled extensive investigation and many clin-
ical trials are underway. Interleukin 2 (IL-2) is a
cytokine immune system activator that stimulates T-
cell proliferation and function besides being used
as a lymphokine-activated cell killer therapy. High-
dose recombinant IL-2 was approved by the FDA in
1998 for treatment due to the potential for durable
complete responses in a small cohort of appropriated
patients [55]. The eﬃciency in administration of
high-dose IL-2 is associated with signiﬁcant toxicity
and, consequently, multiple side eﬀects, so its use
is limited to select patients whose medical care is
done very carefully. Interferon alfa-2b (INF α-2b),
naturally produced cytokine that helps to activate
the immune system, is also considered an adjuvant
therapy of resected high-risk melanoma, but its
eﬀectiveness is not so much better than that already
observed with IL-2;
(iii) Biochemotherapy: this kind of treatment refers
to the most intensive regimens that combine
polychemotherapy or single-agent with immuno-
logical agents INF-α and/or IL-2. The systemic
biochemotherapy has promise, but results from
recent trials have been mixed and inconsistent [56–
58], in part because addition to exposing patient
to consistently high toxicity rates, the responses are
not durable and do not improve overall survival.
While the utility of biochemotherapy is really con-
troversial, in the United States, many melanoma
treatment centers continue to use this therapy for
melanoma[59].Interestingly,itwasrecentlyreported
novelregimenofmaintenancebiotherapyandinduc-
tion biochemotherapy/maintenance biotherapy to
extend progression-free and overall survival, but
this promising regimen will be studied in a ran-
domized clinical trial in patients with advanced
metastatic melanoma [60]. In summary, until today
biochemotherapy regimens cannot be regarded as
standard clinical practice and should be further
evaluated in clinical trials.
5.2. Promising Approaches in Systemic Therapies. Several
attempts to upgrade existing therapies for metastatic
melanoma may not have been successful in clinical studies,
but have revealed remarkable advances to our understanding
of this disease. This signiﬁcant progress is the foundation
for new opportunities of treatments. Currently, two major
trends are recognized for new treatment strategies and both
are involved in the development of therapies that promote
an intervention at the molecular level [61]. One of them isDermatology Research and Practice 7
Table 3: Emerging immunotherapeutic to treatment of metastatic melanoma.
Target Drug Class Phase(s) trial Protocol IDs∗
CD40 CP-870,893 Fully human mAb I NCT01008527
I NCT01103635
CD137 BMS-663513 mAb I NCT00803374
Cytokines Interleukin-21 Recombinant human molecule II NCT01152788
CTLA-4 Tremelimumab Fully human IgG2 mAb III [62]
II NCT01034787
Immunocytokines EMD 273063 Humanized anti-GD2 mAb linked to IL-2 II NCT00590824
αv integrin CNTO95 mAb I, II NCT00246012
αvβ3 integrin MEDI-522 Humanized mAb I NCT00111696




TGF-β GC1008 Fully human mAb I NCT00899444
TGF-β2 AP12009 Antisense oligonucleotide I NCT00844064
TLR regulation of Treg cells CpG 7909 (ProMune) Synthetic oligonucleotide II NCT01266603
No phase speciﬁed NCT00471471
∗Randomized clinical trials selected from http://www.clinicaltrials.gov/.
directly related to the mechanism of immune response of
patients but with a new vision of modulation while the other
aims key biomarkers presented in signaling pathways, which
are highly deregulated along melanoma pathogenesis.
The greatest optimism for advances in the immunother-
apy of melanoma comes from introduction of new agents
and methods that block or avoid the natural regulatory
mechanism, that limit the magnitude of induced T-cell
response, and the tumor-related immunosuppressive mech-
anism [54]. Some of the novel cancer immunotherapies
deserve brief comments.
(i) Immunoregulatorymonoclonalantibodies:cytotoxic
T-lymphocyte antigen (CTLA) is expressed on acti-
vated T lymphocytes and regulatory T cells. It serves
as a natural breaking mechanism that returns T cells
to homeostasis following an immune response, it
controls the duration and intensity of this response.
Monoclonalantibodies(anti-CLTA-4mAb)thatbind
to CTLA-4 inhibit this negative switch and may break
peripheral tolerance to self-tissues and potentiate
immune response against cancer cells. Ipilimumab,
a CTLA-4 blocker of fully human IgG1 monoclonal
antibody class, is the most recently FDA approval
for unresectable or metastatic melanoma. Clinical
trials for monotherapy and the combination with
other immunotherapies and vaccines have been
concluded or are currently underway [62]. Because
of the unusual and severe adverse eﬀects referred
to as autoimmune breakthrough events (ABEs) or
immune-related adverse events (irAEs), the therapy
is being approved with a risk evaluation and mit-
igation strategy to inform healthcare professionals
about these serious risks. Despite this fact, this drug
currently holds great promise for treating patients
with advanced malignant melanoma. Tremelimumab
is an IgG2 monoclonal antibody also directed against
CTLA-4, but the beneﬁts and eﬀects of its use are
still being investigated [63, 64]. Many other targets
related to the immune system are being investi-
gated (Table 3) but owing to complexity of immune
system and presence of molecular immunological
target on multiple cell types, whose eﬀect is cell-
type speciﬁc, the predominant mechanism for an
individual agent’s antitumor activity often cannot be
determined with certainty. Deﬁnitely, combinations
presenting optimal antitumor activity and the right
combinationforeachpatientwilldependontheindi-
vidual’s tumor biology and host factors which makes
it diﬃcult to search for an appropriate therapeutic
strategy [65].
(ii) Adoptive cell transfer (ACT) is a type of adoptive
immunotherapy that involves ex vivo activation and
expansion of autologous tumor-reactive T-cell popu-
lations taken from tumor-bearing host that then are
reinfused back into patient. Several factors may be
obstacles to the eﬀectiveness of this immunotherapy,
such as nonpersistence infused cells in vivo and
possible reduction of infused cells by preexisting Treg
cell. The recent studies demonstrated that activity
of adoptively transferred T cells can be improved
followingonnonmyeloablativelymphodepletingreg-
imen [66]. The lymphodepleting regimen helps to
eliminateTreg cellaswellasnormalendogenouslym-
phocytes that compete with the transferred cells for
homeostatic cytokines and thus promoting increased
circulating cytokines (IL-7 and IL-15) while non-
myeloablative chemotherapy refers to the uses of
moderate doses of chemotherapy, just to suppress the
immune system for a brief period. This evolutionary8 Dermatology Research and Practice
Table 4: Recent report vaccine approaches to advanced malignant melanoma.
Phase trial Purpose and brief comments Reference
II
Treatment of 54 patients with a patient-speciﬁc tumor cell vaccines consisting of
autologous dendritic cells, incubated with IL-4 and suspended in GM-CSF, which
had phagocytized irradiated tumor cells from an autologous tumor cell line.
Treatment was well-tolerated and the projected 5-year survival rate is an impressive
54% at a median followup of 4.5 years for the 30 surviving patients.
[74]
II
Immunization of unresectable stage III or stage IV M1a melanoma patients with
recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B.
The combination of MAGE-A3 and AS15 yielded higher speciﬁc Ab titers, more




To identify markers predictive of the clinical activity of the MAGE-A3
antigen-speciﬁc cancer immunotherapeutic (ASCI) from gene expression proﬁling
by microarrays. A gene-signature derived from pretreatment tumor biopsies has
been developed and shown to predict clinical beneﬁt.
[76]
II
Routinely intratumoral injections of OncoVEXGM−CSF, an oncolytic herpes simplex
virus vector encoding granulocyte monocyte colony-stimulating factor (GM-CSF).
It was observed an improvement rate and durability of response when compared to
other treatment options available to patients with advanced melanoma.
[77]
III
Learn more about the safety and risks of using OncoVEXGM−CSF. Results of a phase




Comparative study between metastatic melanoma patients treated with gp100:
209–217(210M) peptide followed by high-dose IL-2 and high-dose IL-2 alone. The
peptide vaccine plus HD IL-2 promoted signiﬁcant improvement in
progression-free survival (PFS) without a clear impact on survival.
[78]
∗Clinical trials selected from http://www.clinicaltrials.gov/.
technique to treat cancer has demonstrated signiﬁ-
cant progress, mediating objective tumor regressions
in signiﬁcant percentage of patients who stayed on
this treatment [67]; however, it is important to
mention it is not available as standard treatment
for advanced melanoma. Many studies are underway,
and the new investigations are focusing the transfer
of T cell genetically modiﬁed to express melanoma-
speciﬁc T-cell receptors [68].
(iii) Vaccine therapy is an experimental treatment that
aims to stimulate immune system to recognize the
antigens on cancer cell surfaces and be able to pro-
mote an active immunity targeting these malignant
cells. Various strategies are currently being tested,
but, to date, no vaccination procedure has shown
signiﬁcant eﬃcacy in the metastatic setting. The
advance in immunotherapy ﬁeld, like development
anti-CTLA-4 and other immunomodulatory anti-
bodies, may come to improve the outcomes with
vaccine treatment, as they may play a crucial role
in maintaining an immune response initiated by a
vaccine [69]. Many studies are being conducted and
positive experiences recently reported (Table 4)a r e
extremely encouraging for the generation of new
research trials in this area. On the other hand,
some negative results with vaccines have also been
reported,especiallyintheadjuvantsetting,indicating
that multiple vaccinations can have detrimental
eﬀects, perhaps because of induction of tolerance
[70, 71]. Finally, the researches are still continuing
and, despite some previous results, seem promising,
there are many points yet to be clariﬁed, especially
regarding the manner in which the patient’s body
assimilates this type of therapy, which is diﬃcult
clinical progress.
All these data lead to the conclusion that although many
advances have been achieved with immunotherapy, under
combined regimes and/or using the novel immunotherapic
agents, this option for treatment still shows certain limita-
tions to an appropriate standard treatment, mainly due to
severe side eﬀects observed with use of these approaches.
Moreover,thestrategiesthathavehadlessadverseeﬀectsalso
did not demonstrate signiﬁcant eﬃcacy results. In parallel
with these attempts, there is a continuous and growing
understanding of signaling pathways involved in oncogenesis
[72]. Under the context of developing therapies targeted,
these signaling pathways, which are usually altered in speciﬁc
tumor cells, provide new possible targets in hope of gaining
some control over the malignant cells.
Treatment of melanoma focusing on a molecular disease
model: the basis of this principle is the recognition of
melanoma as a heterogeneous disease and that tumorigenic
cells are more variable at a molecular level than can
be observed macro/microscopically [73]. Furthermore, the
concept of “oncogene addition” describes that malignant
cell depends more strongly on hyperactivated pathways thanDermatology Research and Practice 9
Table 5: Principal and secundary melanoma molecular subtypes [73].
Detailed subtypes Pathway(s) Key gene/biomarker(s) Potentially relevant therapeutics
1.1 MAPK BRAF BRAF inhibitors, MEK inhibitors, Hsp90
inhibitors
1.2 MAPK BRAF/PTEN (BRAF inhibitors) AND (PI3K inhibitors, AKT
inhibitors or mTOR inhibitors)
1.3 MAPK BRAF/AKT (BRAF inhibitors) AND (AKT inhibitors or
mTOR inhibitors)
1.4 BRAF/CDK4 BRAF inhibitors AND CDK inhibitors
2.1 c-KIT c-KIT Gleevec & other c-KIT inhibitors
3.1 GNAQ GNA11 GNAQ MEK inhibitors
3.2 GNAQ GNA11 GNA11 MEK inhibitors
4.1 NRAS NRAS MAPK & PI3K inhibitors, Farnesyl transferase
inhibitors
5.1 MITF MITF HDAC inhibitors
6.1 AKT/PI3K PTEN PI3K inhibitors, AKT inhibitors or mTOR
inhibitors
6.2 AKT/PI3K AKT AKT inhibitors or mTOR inhibitors
6.3 AKT/PI3K PI3K PI3K inhibitors, AKT inhibitors or mTOR
inhibitors
7.1 CDK ARF/INK4 CDK inhibitors
7.2 CDK CDK4 CDK inhibitors
7.3 CDK CCND1/Cyclin D1 CDK inhibitors
8.1 PR3/BCL BCL-2 TBD
8.2 PR3/BCL P53 TBD
9 Placeholder for any new subtype of patients that is not currently deﬁned
do normal cells, as well as the speciﬁc activated oncogenes
that drive those pathways. Therefore, this therapeutic oppor-
tunity allows some control over the cancer cells through
precise treatments according to genetic lesion that underlie
each individual disease [2]. It is important to mention that
not all oncogenes can be a treatable target. In general,
powerful targets are enzymes such as kinases, proteases
on account of their catalytic sites which assure satisfactory
selectivity to designed drugs binding. Even now, there are
countless possibilities for molecular targets. This number is
so expressive that it was very recently proposed for formal
process for classifying melanoma into molecular subtypes
and developing proposed treatment guidelines for each
subtype, including speciﬁc assays, drugs, and clinical trials.
This “molecular disease model” can be used by clinicians to
guide treatment decisions, and reﬁned by researchers based
on clinical outcomes and laboratory ﬁndings [73]. Table 5
summarizes the elegant initiative of Vidwans’ research group
who seek through this “dynamic” review article, a faster way
to disseminate relevant new information and the continuous
updating about this point. The table shows types and sub-
types of melanoma in order of importance of the associated
oncogene/tumor suppressor, prevalence, and potential for
therapeutic intervention. According to Vidwans’ research
group,theprincipalsubtypes(1.1–5.1)canactasadominant
oncogeneand,therefore,areimportantfocifortherapywhile
the subtypes described as secondary (6.1–8.1) play support-
ive role and generally coexist with mutations of the major
subtypes. The latest version of the Melanoma Molecular Dis-
ease Model, besides other details, can be found online (avail-
able at http://mmdm.cancercommons.org/ml/index.php/A
Melanoma Molecular Disease Model).
A large and permanently increasing number of pharma-
cologicalinhibitorstargetingseveraloftherecentlyidentiﬁed
mutated signal transduction molecules are being explored
in various clinical trials as shown in Table 6. Most of the
trials are still recruiting patients with advanced malignant
melanoma who have the speciﬁc genetic proﬁle to action
of certain drugs. Although a few of these drugs have been
approved for other types of cancer, as valproic acid, and
sutent, dasatinib, some still have modest activity against
melanoma, for example, sorafenib. As discussed before,
molecular analyses of melanomas have revealed an activated
BRAFV600E mutation as a promising biomarker to test the
eﬃcacy of BRAF-targeted therapy in treating malignant
melanoma. Sorafenib monotherapy has shown to be ineﬃ-
cientbecauseofits lackofspeciﬁcityandlowpotency against
the mutant BRAF [79, 80]. On the other hand, Flaherty
and coauthors [24] conducted a multicenter, phase 1, dose-
escalation clinical trial using PLX4032, a small molecule
that acts selectively by targeting the mutation activated
RAF/MEK/ERK signaling pathway. Afterwards, an extension
phase was performed in order to identify the maximum
dose that could be administered in phase 2 trials without
signiﬁcantly toxicity. As a result, the authors reported
that treatment with PLX4032 at a dose of 960mg orally10 Dermatology Research and Practice
Table 6: Selected drugs for targeted melanoma therapy.
Target(s) Drug Phase(s) trial Protocol IDs∗
BRAF PLX4032 II NCT00949702
III NCT01006980
ARAF
RAF265 In Phase 1 for malignant melanoma NCT00304525 BRAF
CRAF
VEGFR-2
RAFPDGFRVEGFR-2 Sorafenib Modest activity against melanoma —
BRAF GSK2118436 III NCT01227889
II NCT01153763
MEK AZD6244 II NCT00866177
MEK GSK1120212 III NCT01245062
MEK AZD8330 In phase I for (advanced malignancies) NCT00454090
Hsp90 AT13387 In phase I for (solid tumors) NCT00878423
c-KIT Dasatinib II NCT00436605
c-KIT Gleevec III, NCT00470470
II NCT00667953
c-KIT Tasigna III NCT01028222
c-KIT Sutent II NCT00631618
GNAQ GSK1120212 III NCT01245062
GNA11
HDAC Panobinostat I, NCT00925132
III NCT01065467
HDAC1 Valproic acid I NCT00495872
PI3K
SF1126 In phase I for (advanced malignancies) NCT00658671 MTOR1
MTOR2
AKT MK2206 In phase I for (solid tumors) NCT00848718
MTOR OSI-027 In phase I for (advanced solid tumors) NCT00698243
CDK4 Flavopiridol/alvocidib/HMR 1275 II NCT00005971
CDK4 P276-00 II NCT00835419
CDK4 UCN-01 II NCT00072189
∗Randomized clinical trials selected from http://mmdm.cancercommons.org/ml/index.php/A Melanoma Molecular Disease Model.
Table 7: Dual Therapeutic intervention.
Targets Drug Phase(s) trial Protocol IDs∗
BRAF and MEK for the MAPK pathway Sorafenib and Temsirolimus I, II NCT00349206
PI3K, AKT and mTOR for the AKT/PI3K pathway MK2206 plus AZD6244 I NCT01021748
∗Clinical trials selected from http://mmdm.cancercommons.org/ml/index.php/A Melanoma Molecular Disease Model.
twice daily induced responses in the majority of metastatic
melanomas carrying BRAF mutations [24]. Importantly,
Chapman and coworkers [80] are conducting a phase
3 interventional, randomized, controlled and multicenter
clinical trial study (NCT01006980, Table 6) with the purpose
of evaluating progression-free, overall survival, safety and
tolerability of PLX4032 as compared with Dacarbazine in
675 metastatic melanoma patients previously untreated. As
a result just yet, patients with unresectable stage IIIC or
stage IV melanoma (AJCC) positive for BRAFV600E mutation
receiving Vemurafenib (PLX4032, 960 mg orally twice daily)
showed improved rates of overall and progression-free
survival relative to patients who had received Dacarbazine
(1000mg/m2 of body surface area intravenously every 3
weeks) [80]. Taken together, these successes highlight the
importanceofamoleculardiseasemodelfocusingonspeciﬁc
biomarkers,suchasBRAFV600E mutation,asbonaﬁdetargets
which could beneﬁt melanoma patients. Another hypothesis
to explain low activity of Sorafenib in melanoma cells is the
possibility that melanoma cell proliferation could be driven
by alternative pathways when RAF/MEK/ERK signaling
is blocked [79, 81]. Based on this, several studies using
inhibitors of distinct pathways have been initiated (Table 7)
and encouraging response rates have been reported [82].Dermatology Research and Practice 11
The amount of studies presented here and the emergence
of new therapeutic opportunities show that the scientiﬁc
community is really committed to ﬁnding the best way to
overcome this challenge, the treatment for metastatic malig-
nant melanoma. Since melanoma is much more than a single
disease, the real beneﬁt most likely will be require the use
of multiple strategies together (chemotherapy, immunother-
apy, targeted therapy). But if on one hand the positive
synergistic eﬀect of these agents is achieved by the other, an
extra burden of toxicity and unknown events arising from
the interaction of these agents cannot be ignored. It is known
that, besides the intrinsic characteristics of each person, the
biologyofmelanoma,aswellasothertypesofcancer,hasalso
a few distinct characteristics even among patients in same
disease stage, which leads us to another challenge, before
treatment choice: identifying the tumors and patients that
best suited to respond to certain therapies.
6. Conclusion
Recent discoveries have provided fascinating insights into
malignant melanoma development. It is clear that dereg-
ulation in distinct oncogenes and tumor suppressors are
involved in malignant melanoma progression, as evaluated
by results of compiled studies presented here. Thus, there are
evidences in which more than one route leads to melanocyte
full malignant transformation and melanoma progression.
The major question to be considered by researchers,
clinicians, and dermatopathologists is the limited success
of discovered biomarkers to predict or identify groups
of patients with substantial risk for metastasis. Unfortu-
nately, no reliable biomarker that signiﬁcantly translates
into eﬀectiveness therapeutic responses and overall median
survival rate beneﬁts to patients with advanced disease has
been identiﬁed. Perhaps, this characteristic can be due to
melanoma heterogeneity, substantial diﬀerences in experi-
mental and clinical trials design, inadequate classiﬁcation
schemes, environmental-associated risk factors, and person’s
condition such as age, gender, and immune competence.
Although a true biomarker is a molecule capable of dis-
tinguishing a speciﬁc stage of disease, the data reported
here strongly suggest that understanding primary clonal
events that occur in primary malignant melanomas through
melanoma classiﬁcation reﬁnement may help us to identify
molecular marks acting immediately downstream. These
secondary alterations provide new insights for predicting the
metastatic behavior in a more stable genomic, epigenomic,
and metabolomic context. Hence, additional studies are
required to identify distinct subpopulations of melanoma
cells, including circulating tumor-initiating cells in attempt
to identify these distinct molecular pathways and classify,
in a more reliable way, patient candidates for further per-
sonalized medicine. Recently, Vidwans’ group (2011) devel-
oped a molecular disease model that classiﬁes melanomas
into molecular subtypes based on genetic status of key
biomarker(s)/pathway(s) and their combination, which are
potential targets for existing therapeutic interventions [73].
This molecular classiﬁcation of melanomas might be a
powerful strategy used to reﬁne melanoma classiﬁcation and
toguideappropriatetargettherapy.Thus,becausemelanoma
is a heterogeneous disease, biomarkers can allow us to
identify patients who best respond to certain therapeutic
approach. And therefore standard treatments are currently
available to be based primarily on usage, together or
not, chemotherapies (dacarbazine) or/and imunotherapies
(high-dose recommbinant IL-2, Ipilimumab), but require a
rigorous preclinical evaluation as well as a constant medical
supervision. On the other hand, another barrier for studying
and treating melanoma metastasis is the limited availability
of fresh melanoma tissues representing early stages of disease
and adjacent normal skin. Because of this, diﬀerent sources
canbeexploitedtoinitialscreening,suchasananimalmodel
that mimicries the “natural” evolution of disease. In this way,
a murine melanoma progression model developed by our
group [83] has shown good correlation with data reported
in humans, especially with respect to epigenetic therapy,
highlighting the potential translational application from the
basic research to clinical research, which might be especially
important in metastatic disease [16]. In conclusion, the
characterization of distinct subpopulations of melanoma
cells and signaling pathways by integrating classiﬁcation
scheme opens the avenue to the development of more
responsive antimelanoma therapy.
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